Merck KGaA Expects Core Franchises, Alliances To Strengthen In China
Merck KGaA's healthcare business in China will continue to center around its fertility, general medicines and endocrinology therapies while also building on new corporate alliances there, the German conglomerate’s global operations head told Scrip.
You may also be interested in...
The German group is predicting sales of its new MS drug Mavenclad in the mid-triple digit million euro range worldwide in 2019 if all goes well across the Atlantic.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.